Omega-3 (EPA/DHA)
Also known as: Fish Oil, EPA, DHA, Icosapent Ethyl, Vascepa, Lovaza, N-3 fatty acids
Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
A dietary fatty acid supplement. No anabolic, androgenic or ergogenic action: it does not raise the natural ceiling. Included because triglyceride elevation and cardiovascular risk are real consequences of long-term AAS use and this is the most commonly used intervention for the triglyceride side. Rated 1 (basically natty).
Overview
The most commonly taken supplement in this entire archive, and one where the honest evidence is narrower than the reputation. It genuinely and reliably lowers triglycerides in a dose-dependent way. Whether it reduces cardiovascular events is a far more contested question, two large trials of the same broad idea reached opposite conclusions.
Important Warnings
- •Dose figures are combined EPA+DHA, NOT total fish oil, most people under-dose by a large margin
- •Increased atrial fibrillation incidence has been observed in the high-dose (4g/day) outcome trials
- •It lowers triglycerides; it does NOT fix the LDL elevation or HDL suppression from oral steroids
- •The cardiovascular-outcome evidence is contested: REDUCE-IT was positive, STRENGTH was null
- •REDUCE-IT's mineral oil placebo may have exaggerated its apparent benefit
- •Disclose use before surgery and if taking anticoagulants
Purpose & Use Cases
Lowering Triglycerides
The well-supported use. The AHA has recommended 2-4 grams per day of EPA plus DHA for reducing triglycerides in patients with elevated levels, and the effect is clearly dose-dependent.
General Cardiovascular Support On Long-Term Cycles
Part of the standard support protocol for anyone on extended TRT or repeated blasts. Worth being clear that this is a supporting measure. It is not a substitute for a statin when LDL is the problem.
Benefits
- A daily dose of 4g EPA+DHA lowers triglycerides by 20-30% in adults with levels of 200-499 mg/dL, and by more than 30% in those above 500 mg/dL
- Meta-analyses across 49 studies show a mean triglyceride drop of 25% at 4g/day and 14% at 2g/day
- Lowers triglycerides without raising LDL cholesterol
- AHA advisory concluded prescription n-3 at 4g/day is effective and safe for triglyceride reduction, alone or added to other lipid-lowering agents
- Very well tolerated, cheap and available without prescription
- No hormonal interaction and no PCT implications
Good to Know
Grams of EPA+DHA, not grams of fish oil
The dosing figures in every trial refer to combined EPA plus DHA content. A standard 1000mg fish oil capsule commonly contains only around 300mg of that. Someone taking two capsules a day and believing they are at a therapeutic dose is roughly an order of magnitude short.
REDUCE-IT and STRENGTH reached opposite conclusions
REDUCE-IT found icosapent ethyl (EPA-only ethyl ester) produced a statistically significant 4.8% absolute risk reduction in its primary endpoint, with cardiovascular death at 4.3% versus 5.2% on placebo. STRENGTH, testing a carboxylic acid formulation of EPA plus DHA, found no effect on major adverse cardiovascular events in statin-treated high-risk patients. Same broad hypothesis, opposite results.
The mineral oil problem
The REDUCE-IT result is contested because its control arm used mineral oil, which had unfavourable effects on cholesterol and inflammatory markers and may therefore have exaggerated the apparent benefit of the active drug. STRENGTH used corn oil and found nothing. Anyone citing REDUCE-IT as settled proof is skipping the most-discussed caveat in the field.
It is a triglyceride drug, not an LDL drug
For AAS-driven dyslipidemia the dominant problems are elevated LDL and suppressed HDL. Omega-3 addresses neither. Taking fish oil and considering your lipids managed is a common and consequential mistake, that job belongs to a statin, and to coming off the compound causing it.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 1 – 2 g/day |
| Intermediate | 2 – 4 g/day |
CRITICAL: these figures are grams of COMBINED EPA + DHA, not grams of fish oil. This is the single most common dosing error with this supplement, a typical 1000mg fish oil capsule often contains only about 300mg of actual EPA+DHA, so hitting 2-4g of EPA+DHA can mean six to twelve capsules of a standard product, not two. Read the EPA and DHA figures on the label rather than the capsule size. The AHA has recommended 2-4g/day of EPA+DHA for elevated triglycerides; effects are measured at 8-12 weeks, not days. Prescription formulations deliver these doses in far fewer capsules.
EPA and DHA are incorporated into cell membranes over weeks rather than cleared like a drug, which is why triglyceride effects are measured at 8-12 weeks rather than in days. Membrane omega-3 content (the "omega-3 index") is the meaningful measure of exposure, not a plasma half-life.
Side Effects
Fishy aftertaste / reflux / burping
very commonThe near-universal complaint, and worse at the higher doses actually needed to move triglycerides.
Take with food, split the dose, freeze the capsules, or use an enteric-coated or prescription formulation.
Gastrointestinal upset / loose stools
commonDose-dependent, and more likely at the 4g/day end of the range.
Split doses across meals and titrate up gradually.
Atrial fibrillation risk at high doses
uncommonAn increased incidence of atrial fibrillation has been observed in the high-dose omega-3 cardiovascular outcome trials, a signal that emerged specifically at the 4g/day prescription-strength doses rather than at supplement doses.
Relevant when using 4g/day. Report palpitations or irregular heartbeat.
Bleeding risk (theoretical at high doses)
rareOmega-3s affect platelet function; relevance rises with anticoagulant use and high doses.
Disclose use before surgery and if taking anticoagulants.
General Mitigation Strategies
Practically speaking the burden is reflux and aftertaste rather than toxicity, and both are manageable with formulation and timing. The one genuine safety signal worth knowing is the atrial fibrillation incidence observed in the high-dose outcome trials, which applies at 4g/day rather than at ordinary supplement doses.
Post Cycle Therapy (PCT)
No HPT axis interaction. No PCT implications.
How It Works
EPA and DHA reduce hepatic production of very-low-density lipoprotein and increase triglyceride clearance, producing a dose-dependent fall in serum triglycerides. They are incorporated into cell membranes where they influence eicosanoid signalling and inflammatory pathways. The mechanism behind the disputed cardiovascular-outcome effect, and whether it is specific to EPA rather than EPA plus DHA, is precisely what the conflicting trial results have failed to settle.
Hormonal & Androgenic Profile
N/A: not an androgen.
Not a hormonal compound.
Reliably lowers triglycerides in a dose-dependent way without raising LDL. Whether that translates into fewer cardiovascular events is genuinely unresolved. See keyFacts on REDUCE-IT versus STRENGTH. It does not meaningfully address the LDL elevation or HDL suppression caused by oral steroids.
Fundamentals
Reference on the practices relevant to Omega-3 (EPA/DHA): how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- Omega-3 + Rosuvastatin: triglycerides and LDL are different problems with different drugs
- Omega-3 as general cardiovascular support on long-term TRT
- Do NOT rely on omega-3 alone as lipid protection during oral 17-AA cycles
Legal Status
Fish oil is sold freely as a dietary supplement. Prescription-strength formulations exist and are FDA-approved for severe hypertriglyceridemia, icosapent ethyl (EPA only) and mixed EPA/DHA preparations. The prescription and supplement forms are not interchangeable at the doses used clinically.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
A dietary fatty acid supplement with no performance-enhancing action. Not listed on the WADA Prohibited List.
References
- AHA Science Advisory (Circulation 2019): Omega-3 Fatty Acids for the Management of Hypertriglyceridemia
- Circulation, Omega-3 for Cardiovascular Diseases: Where Do We Stand After REDUCE-IT and STRENGTH?
- Frontiers in Nutrition (2024): Unraveling the discrepancies between REDUCE-IT and STRENGTH trials with omega-3 fatty acids
- NIH Office of Dietary Supplements, Omega-3 Fatty Acids Health Professional Fact Sheet